Another example showing the utility of the BRAFV600E mutant-specific gene expression signature as a target for novel candidate therapy in CRC was provided by San Lucas et al. [8], who employed an in silico approach to reveal specific gene expression signatures of BRAFV600E mutant CRC as compared to BRAF wild-type CRC and identified EGFR inhibitor gefitinib and proteasome inhibitor MG-262 as potential candidate drugs to specifically treat BRAFV600E CRC. Here, EGFR is linked to colorectal carcinoma.